Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Relmada Therapeutics, a clinical-stage biotech company focused on oncology and CNS disorders, will report its second quarter 2026 financial results on August 6, 2026. The company will host a conference call and webcast to discuss financials and recent progress of its mid-stage clinical candidates NDV-01 and sepranolone.